Litigation Details for SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)
✉ Email this page to a colleague
SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-07-06 |
| Court | District Court, D. New Jersey | Date Terminated | 2022-07-31 |
| Cause | 15:1126 Patent Infringement | Assigned To | Claire Claudia Cecchi |
| Jury Demand | Plaintiff | Referred To | Mark Falk |
| Parties | HUAHAI US INC. | ||
| Patents | 10,030,060; 6,063,927; 6,080,759; 6,113,944; 6,172,233; 7,598,271; 8,658,663; 8,946,251; 9,375,388; 9,393,237 | ||
| Attorneys | JOHN COLEMAN LIFLAND | ||
| Firms | Jams | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-07-06 | 1 | Label (April 2017), # 2 Exhibit B: U.S. Patent No. 9,393,237, # 3 Exhibit C: Actavis ANDA Approved Labeling…2017 31 July 2022 2:17-cv-04964 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document | |
| 2017-07-08 | 10 | U.S. Patent No. 9,393,237, # 4 Exhibit 3: U.S. Patent No. 8,658,663, # 5 Exhibit 4: U.S. Patent No. 8,946,251…2017 31 July 2022 2:17-cv-04964 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document | |
| 2017-07-10 | 11 | HOLDER or l'ATENT OR TRADEMARK. I us 9,393,237 7/19/2016 … ~ 0 Trademarks or ~Patents. ( O the patent action involves 35 U.S.C. § 292.): DOCKET… AO120 Patent Form filed. (jr) (Entered: 07/10/2017) 10 July 2017 PACER Document … REPORT ON THE Director of the U.S. Patent and Trademark Office … ACTION REGARDING A PATENT OR Alexandria, VA 22313 | External link to document | |
| 2017-07-20 | 22 | and administered at 0.01, 1.0, 10, 30 60 mg/kg) or 1-[1-(3-chlorophenyl)-2-(4-methyl- …fluoxetine (Sigma, dissolved in sterile H20 at 10, 30, 60 mg/kg) or combination of fluoxetine ·administered…in sterile H2 0 and administered at 1.0, 10, 30, 60 mg/kg) 1 hour prior to naloxone. Venlafaxine …dissolved in sterile H20 and administered at 1.0, 10, 30, 60 mg/kg), S- enantiomer of .oov …dissolved in sterile H20 and administered at 1.0, 10, 30, 60 mg/kg), or paroxetine (which was synthesized | External link to document | |
| 2017-07-25 | 26 | U.S. Patent No. 5,955,475, # 3 Exhibit 35: U.S. Patent No. 6,113,944, # 4 Exhibit 36: U.S. Patent No. …6,645,523, # 5 Exhibit 37: U.S. Patent No. 6,660,298, # 6 Exhibit 38: U.S. Patent No. 6,699,882, # 7 Exhibit…40: U.S. Patent Application Publication No. 2004/0067254 (Lemmens), # 9 Exhibit 41: U.S. Patent No. 6,369,051…2017 31 July 2022 2:17-cv-04964 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
